

10/539501

JC05 Rec'd PCT/PTO 17 JUN 2005  
CASE LR/G-32980A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
KRISCH ET AL.  
INTERNATIONAL APPLICATION NO: PCT/SI2003/000045  
FILED: 11 DECEMBER 2003  
U.S. APPLICATION NO: Not Yet Known  
35 USC §371 DATE: Herewith  
FOR: TREATMENT OF PSYCHOSTIMULANT ADDICTION

**MS: Amendment**  
Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:


This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/SI2003/000045, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

  
John D. Thallemer  
Attorney for Applicants  
Reg. No. 34,940

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7945  
Date: June 17, 2005

10/539501

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE  
INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.  
LR/G-3298  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
KRISCH ET AL.  
FILING DATE  
Herewith

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	4,935,429	6/19/90	Dackis et al.			
	AB	5,430,031	7/4/95	Brambilla et al.			
	AC	5,441,961	8/15/95	Cohen et al.			
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	NO
	AM	01/41763	6/14/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN						<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Milivojevic et al., "A Novel Ergoline Derivative LEK-8829 Attenuates Cocaine-Induced Reinstatement of Cocaine-Seeking Behavior", Behavioural Pharmacology, Vol. 14, No. Suppl. 1, p. S55 (2003).
AS	Glavan et al., "Modulation of Neuroleptic Activity of 9,10-didehydro-N-methyl-(2-propynyl)-6-methyl-8-aminomethylergoline bimaleinate (LEK-8829) by D1 Intrinsic Activity in Hemi-Parkinsonian Rats", Molecular Pharmacology, Vol. 61, No. 2, pp. 360-368 (2002).
AT	Zivin et al., "Antiparkinsonian Potential of Interaction of LEK-8829 with Bromocriptine", European Journal of Pharmacology, Vol. 349, No. 2-3, pp. 151-157 (1998).

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.